.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Fuji
Novartis
Julphar
Farmers Insurance
Chinese Patent Office
Daiichi Sankyo
Fish and Richardson
Mallinckrodt

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Stable heterodimeric antibody design with mutations in the Fc domain
Abstract: The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.
Inventor(s): Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA)
Assignee: Zymeworks Inc. (Vancouver, CA)
Application Number:13/668,098
Patent Claims:1. An isolated heteromultimer comprising a modified heterodimeric CH3 domain comprising a first CH3 domain polypeptide and a second CH3 domain polypeptide, the first and second CH3 domain polypeptides independently comprising amino acid modifications as compared to a wild-type CH3 domain polypeptide, wherein the first CH3 domain polypeptide comprises amino acid modifications at positions T350, L351, F405, and Y407, and the second CH3 domain polypeptide comprises amino acid modifications at positions T350, T366, K392 and T394, wherein the amino acid modification at position T350 is T350V, T3501, T350L or T350M; the amino acid modification at position L351 is L351Y; the amino acid modification at position F405 is F405A, F405V, F405T or F405S; the amino acid modification at position Y407 is Y407V, Y407A or Y407I; the amino acid modification at position T366 is T366L, T366I, T366V, or T366M, the amino acid modification at position K392 is K392F, K392L or K392M, and the amino acid modification at position T394 is T394W, and wherein the numbering of amino acid residues is according to the EU index as set forth in Kabat.

2. A composition comprising the isolated heteromultimer according to claim 1 and a pharmaceutically acceptable carrier.

3. The isolated heteromultimer according to claim 1, wherein the amino acid modification at position K392 is K392M or K392L.

4. The isolated heteromultimer according to claim 1, wherein the amino acid modification at position T350 is T350V.

5. The isolated heteromultimer according to claim 3, wherein the first CH3 domain polypeptide further comprises one or more amino acid modifications selected from Q347R and one of S400R or S400E.

6. The isolated heteromultimer according to claim 3, wherein the second CH3 domain polypeptide further comprises one or more amino acid modifications selected from L351Y, K360E, and one of N390R, N390D or N390E.

7. The isolated heteromultimer according to claim 3, wherein the first CH3 domain polypeptide further comprises one or more amino acid modifications selected from Q347R and one of S400R or S400E, and the second CH3 domain polypeptide further comprises one or more amino acid modifications selected from L351Y, K360E, and one of N390R, N390D or N390E.

8. The isolated heteromultimer according to claim 3, wherein the amino acid modification at position T350 is T350V.

9. The isolated heteromultimer according to claim 8, wherein the amino acid modification at position F405 is F405A.

10. The isolated heteromultimer according to claim 8, wherein the amino acid modification at position Y407 is Y407V.

11. The isolated heteromultimer according to claim 8, wherein the amino acid modification at position T366 is T366L or T366I.

12. The isolated heteromultimer according to claim 1, wherein the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is and Y407V, the amino acid modification at position T366 is T366L or T366I, and the amino acid modification at position K392 is K392M or K392L.

13. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405V and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W.

14. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405T and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W.

15. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405S and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392M and T394W.

16. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, T366L, N390R, K392M and T394W.

17. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications Q347R, T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, K360E, T366L, N390R, K392M and T394W.

18. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390D, K392M and T394W.

19. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390E, K392M and T394W.

20. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392L and T394W.

21. The isolated heteromultimer according to claim 7, wherein the first CH3 domain polypeptide comprises the amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, T366L, N390R, K392F and T394W.

22. The isolated heteromultimer according to claim 1, wherein the modified heterodimeric CH3 domain is comprised by an Fc construct based on a type G immunoglobulin (IgG).

23. The isolated heteromultimer according to claim 22, wherein the IgG is an IgG1, IgG2, IgG3 or IgG4.

24. The isolated heteromultimer according to claim 23, wherein the IgG is an IgG1.

25. The isolated heteromultimer according to claim 1, wherein said heteromultimer is a bispecific antibody or a multispecific antibody.

26. The isolated heteromultimer according to claim 25, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.

27. The isolated heteromultimer according to claim 25, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain from a therapeutic antibody.

28. The isolated heteromultimer according to claim 27, wherein the therapeutic antibody is selected from the group consisting of abagovomab, adalimumab, alemtuzumab, aurograb, bapineuzumab, basiliximab, belimumab, bevacizumab, briakinumab, canakinumab, catumaxomab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, galiximab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, lumiliximab, mepolizumab, motavizumab, muromonab, mycograb, natalizumab, nimotuzumab, ocrelizumab, ofatumumab, omalizumab, palivizumab, panitumumab, pertuzumab, ranibizumab, reslizumab, rituximab, teplizumab, tocilizumab/atlizumab, tositumomab, trastuzumab, anti-EpCAM-Pseudomonas-exotoxin fusion protein, girentuximab, ustekinumab, and zalutumumab.

29. The isolated heteromultimer according to claim 27 comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first and second antigen-binding domains are from the same therapeutic antibody.

30. The isolated heteromultimer according to claim 27 comprising a first antigen-binding domain and a second antigen-binding domain, wherein the first and second antigen-binding domains are from different therapeutic antibodies.

31. The isolated heteromultimer according to claim 25, wherein the bispecific antibody or multispecific antibody is conjugated to a therapeutic agent.

32. An isolated heteromultimer comprising a modified heterodimeric CH3 domain comprising: a first CH3 domain polypeptide comprising amino acid modifications T350V, L351Y, F405A and Y407V, and a second CH3 domain polypeptide comprising amino acid modifications T350V, T366L, K392L and T394W.

33. An isolated heteromultimer comprising a modified heterodimeric CH3 domain comprising: a first CH3 domain polypeptide comprising amino acid modifications T350V, L351Y, F405A and Y407V, and a second CH3 domain polypeptide comprising amino acid modifications T350V, T366L, K392M and T394W.

34. An isolated heteromultimer comprising a modified heterodimeric CH3 domain comprising: a first CH3 domain polypeptide comprising amino acid modifications T350V, L351Y, S400R, F405A and Y407V, and a second CH3 domain polypeptide comprising amino acid modifications T350V, T366L, K392M and T394W.

35. An isolated heteromultimer comprising a modified heterodimeric CH3 domain comprising: a first CH3 domain polypeptide comprising amino acid modifications T350V, L351Y, S400E, F405A and Y407V, and a second CH3 domain polypeptide comprising amino acid modifications T350V, T366L, N390R, K392M and T394W.

36. The isolated heteromultimer according to claim 32, wherein the modified heterodimeric CH3 domain is comprised by an Fc construct based on a type G immunoglobulin (IgG).

37. The isolated heteromultimer according to claim 36, wherein the IgG is an IgG1.

38. The isolated heteromultimer according to claim 32, wherein said heteromultimer is a bispecific antibody or a multispecific antibody.

39. The isolated heteromultimer according to claim 38, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.

40. The isolated heteromultimer according to claim 39, wherein the cancer antigen is HER2, HER3 or EGFR.

41. The isolated heteromultimer according to claim 38, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain from a therapeutic antibody.

42. The isolated heteromultimer according to claim 41, wherein the therapeutic antibody is selected from the group consisting of abagovomab, adalimumab, alemtuzumab, aurograb, bapineuzumab, basiliximab, belimumab, bevacizumab, briakinumab, canakinumab, catumaxomab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, galiximab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, lumiliximab, mepolizumab, motavizumab, muromonab, mycograb, natalizumab, nimotuzumab, ocrelizumab, ofatumumab, omalizumab, palivizumab, panitumumab, pertuzumab, ranibizumab, reslizumab, rituximab, teplizumab, tocilizumab/atlizumab, tositumomab, trastuzumab, anti-EpCAM-Pseudomonas-exotoxin fusion protein, girentuximab, ustekinumab, and zalutumumab.

43. The isolated heteromultimer according to claim 41 comprising a first antigen-binding domain and a second antigen-binding domain, wherein (a) the first and second antigen-binding domains are from the same therapeutic antibody, or (b) the first and second antigen-binding domains are from different therapeutic antibodies.

44. The isolated heteromultimer according to claim 38, wherein the bispecific antibody or multispecific antibody is conjugated to a therapeutic agent.

45. The isolated heteromultimer according to claim 33, wherein the modified heterodimeric CH3 domain is comprised by an Fc construct based on a type G immunoglobulin (IgG).

46. The isolated heteromultimer according to claim 45, wherein the IgG is an IgG1.

47. The isolated heteromultimer according to claim 33, wherein said heteromultimer is a bispecific antibody or a multispecific antibody.

48. The isolated heteromultimer according to claim 47, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.

49. The isolated heteromultimer according to claim 48, wherein the cancer antigen is HER2, HER3 or EGFR.

50. The isolated heteromultimer according to claim 47, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain from a therapeutic antibody.

51. The isolated heteromultimer according to claim 50, wherein the therapeutic antibody is selected from the group consisting of abagovomab, adalimumab, alemtuzumab, aurograb, bapineuzumab, basiliximab, belimumab, bevacizumab, briakinumab, canakinumab, catumaxomab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, galiximab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, lumiliximab, mepolizumab, motavizumab, muromonab, mycograb, natalizumab, nimotuzumab, ocrelizumab, ofatumumab, omalizumab, palivizumab, panitumumab, pertuzumab, ranibizumab, reslizumab, rituximab, teplizumab, tocilizumab/atlizumab, tositumomab, trastuzumab, anti-EpCAM-Pseudomonas-exotoxin fusion protein, girentuximab, ustekinumab, and zalutumumab.

52. The isolated heteromultimer according to claim 50 comprising a first antigen-binding domain and a second antigen-binding domain, wherein (a) the first and second antigen-binding domains are from the same therapeutic antibody, or (b) the first and second antigen-binding domains are from different therapeutic antibodies.

53. The isolated heteromultimer according to claim 47, wherein the bispecific antibody or multispecific antibody is conjugated to a therapeutic agent.

54. The isolated heteromultimer according to claim 34, wherein the modified heterodimeric CH3 domain is comprised by an Fc construct based on a type G immunoglobulin (IgG).

55. The isolated heteromultimer according to claim 54, wherein the IgG is an IgG1.

56. The isolated heteromultimer according to claim 34, wherein said heteromultimer is a bispecific antibody or a multispecific antibody.

57. The isolated heteromultimer according to claim 56, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.

58. The isolated heteromultimer according to claim 57, wherein the cancer antigen is HER2, HER3 or EGFR.

59. The isolated heteromultimer according to claim 56, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain from a therapeutic antibody.

60. The isolated heteromultimer according to claim 59, wherein the therapeutic antibody is selected from the group consisting of abagovomab, adalimumab, alemtuzumab, aurograb, bapineuzumab, basiliximab, belimumab, bevacizumab, briakinumab, canakinumab, catumaxomab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, galiximab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, lumiliximab, mepolizumab, motavizumab, muromonab, mycograb, natalizumab, nimotuzumab, ocrelizumab, ofatumumab, omalizumab, palivizumab, panitumumab, pertuzumab, ranibizumab, reslizumab, rituximab, teplizumab, tocilizumab/atlizumab, tositumomab, trastuzumab, anti-EpCAM-Pseudomonas-exotoxin fusion protein, girentuximab, ustekinumab, and zalutumumab.

61. The isolated heteromultimer according to claim 59 comprising a first antigen-binding domain and a second antigen-binding domain, wherein (a) the first and second antigen-binding domains are from the same therapeutic antibody, or (b) the first and second antigen-binding domains are from different therapeutic antibodies.

62. The isolated heteromultimer according to claim 56, wherein the bispecific antibody or multispecific antibody is conjugated to a therapeutic agent.

63. The isolated heteromultimer according to claim 35, wherein the modified heterodimeric CH3 domain is comprised by an Fc construct based on a type G immunoglobulin (IgG).

64. The isolated heteromultimer according to claim 63, wherein the IgG is an IgG1.

65. The isolated heteromultimer according to claim 35, wherein said heteromultimer is a bispecific antibody or a multispecific antibody.

66. The isolated heteromultimer according to claim 65, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain that binds a cancer antigen.

67. The isolated heteromultimer according to claim 66, wherein the cancer antigen is HER2, HER3 or EGFR.

68. The isolated heteromultimer according to claim 65, wherein the bispecific antibody or multispecific antibody comprises at least one antigen-binding domain from a therapeutic antibody.

69. The isolated heteromultimer according to claim 68, wherein the therapeutic antibody is selected from the group consisting of abagovomab, adalimumab, alemtuzumab, aurograb, bapineuzumab, basiliximab, belimumab, bevacizumab, briakinumab, canakinumab, catumaxomab, certolizumab pegol, cetuximab, daclizumab, denosumab, efalizumab, galiximab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, lumiliximab, mepolizumab, motavizumab, muromonab, mycograb, natalizumab, nimotuzumab, ocrelizumab, ofatumumab, omalizumab, palivizumab, panitumumab, pertuzumab, ranibizumab, reslizumab, rituximab, teplizumab, tocilizumab/atlizumab, tositumomab, trastuzumab, anti-EpCAM-Pseudomonas-exotoxin fusion protein, girentuximab, ustekinumab, and zalutumumab.

70. The isolated heteromultimer according to claim 68 comprising a first antigen-binding domain and a second antigen-binding domain, wherein (a) the first and second antigen-binding domains are from the same therapeutic antibody, or (b) the first and second antigen-binding domains are from different therapeutic antibodies.

71. The isolated heteromultimer according to claim 65, wherein the bispecific antibody or multispecific antibody is conjugated to a therapeutic agent.

72. The isolated heteromultimer according to claim 1, wherein the first CH3 domain polypeptide further comprises the amino acid modification Y349C, and the second CH3 domain polypeptide further comprises the amino acid modification S354C.

73. The isolated heteromultimer according to claim 72, wherein the first CH3 domain polypeptide comprises the amino acid modifications Y349C, T350V, L351Y, S400E, F405A and Y407V, and the second CH3 domain polypeptide comprises the amino acid modifications T350V, S354C, T366L, N390R, K392M and T394W.

74. The isolated heteromultimer according to claim 26, wherein the cancer antigen is HER2, HER3 or EGFR.

75. The isolated heteromultimer according to claim 1, wherein the heterodimeric CH3 domain has a melting temperature (Tm) of between 74.degree. C. and about 83.degree. C. and a purity of at least 95%.

76. The isolated heteromultimer according to claim 4, wherein the amino acid modification at position F405 is F405A.

77. The isolated heteromultimer according to claim 4, wherein the amino acid modification at position Y407 is Y407V.

78. The isolated heteromultimer according to claim 4, wherein the amino acid modification at position T366 is T366L or T366I.

79. The isolated heteromultimer according to claim 4, wherein the amino acid modification at position F405 is F405A, the amino acid modification at position Y407 is Y407V, the amino acid modification at position T366 is T366L or T366I, and the amino acid modification at position K392 is K392L or M.

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
RITUXAN
rituximab
VIAL1037050011997-11-26► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXsearch
Novartis
SIMULECT
basiliximab
VIAL; SINGLE-USE1037640011998-05-12► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXsearch
Novartis
SIMULECT
basiliximab
VIAL; SINGLE-USE1037640021998-05-12► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXsearch
Medimmune
SYNAGIS
palivizumab
VIAL1037700011998-06-19► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXsearch
Medimmune
SYNAGIS
palivizumab
VIAL1037700021998-06-19► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXsearch
Centocor Inc
REMICADE
infliximab
VIAL1037720011998-08-24► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXOrphansearch
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXOrphansearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480012001-05-07► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXOrphansearch
Genzyme
CAMPATH
alemtuzumab
VIAL; INTRAVENOUS1039480022001-05-07► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXOrphansearch
Genzyme
LEMTRADA
alemtuzumab
INJECTABLE;INJECTION1039480032001-05-07► Subscribe Zymeworks Inc. (Vancouver, CA) Spreter Von Kreudenstein; Thomas (Vancouver, CA), Dixit; Surjit Bhimarao (Richmond, CA), Escobar-Cabrera; Eric (Burnaby, CA), Lario; Paula Irene (Vancouver, CA), Poon; David Kai Yuen (Richmond, CA) ► SubscribeRXOrphansearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2012332021Jun 19, 2014
Australia2013258844Dec 04, 2014
Australia2013289881Feb 26, 2015
Australia2013289883Feb 19, 2015
Australia2013337578May 21, 2015
Australia2014287011Feb 25, 2016
Australia2014287011Mar 10, 2016
Australia2015206407Aug 18, 2016
Brazil112014010580May 02, 2017
Canada2854233May 10, 2013
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Harvard Business School
Chinese Patent Office
Novartis
Dow
Colorcon
Cantor Fitzgerald
McKinsey
Baxter
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot